Pasteur Institute of Iran, Dept. of Hepatitis B Vaccine Production, Research & Production Complex, Karaj, Iran.
Pasteur Institute of Iran, Dept. of Immunology, Hybridoma Lab, Tehran, Iran.
PLoS One. 2022 Jul 25;17(7):e0267206. doi: 10.1371/journal.pone.0267206. eCollection 2022.
Efficient Bio-immunomagnetic separation (BIMS) of recombinant hepatitis B surface antigen (rHBsAg) with high binding capacity was studied using affinity ligand immobilized bacterial magnetosome nanoparticles (Magnetospirillum gryphiswaldense strain MSR-1 bacteria) as an immunomagnetic sorbent. Our results showed immunomagnetic adsorption, acted by affinity interactions with the immobilized monoclonal antibody, offered higher antigen adsorption and desorption capacities as compared with the commercially available immunoaffinity sorbents. Four different ligand densities of the Hep-1 monoclonal antibody were examined during covalent immobilization on Pyridyl Disulfide-functionalized magnetosome nanoparticles for HBsAg immunomagnetic separation. The average of adsorption capacity was measured as 3 mg/ml in optimized immunomagnetic sorbent (1.056 mg rHBsAg/ml immunomagneticsorbent/5.5 mg of total purified protein) and 5mg/ml in immunoaffinity sorbent (0.876 mg rHBsAg/ml immunosorbent/5.5 mg total purified protein during 8 runs. Immunomagnetic sorbent demonstrated ligand leakage levels below 3 ng Mab/Ag rHBsAg during 12 consecutive cycles of immunomagnetic separation (IMS). The results suggest that an immunomagnetic sorbent with a lower ligand density (LD = 3 mg Mab/ml matrix) could be the best substitute for the immunosorbent used in affinity purification of r-HBsAg there are significant differences in the ligand density (98.59% (p-value = 0.0182)), adsorption capacity (97.051% (p-value = 0.01834)), desorption capacity (96.06% (p-value = 0.036)) and recovery (98.97% (p-value = 0.0231)). This study indicates that the immunosorbent approach reduces the cost of purification of Hep-1 protein up to 50% as compared with 5 mg Mab/ml immunoaffinity sorbent, which is currently used in large-scale production. As well, these results demonstrate that bacterial magnetosome nanoparticles (BMs) represent a promising alternative product for the economical and efficient immobilization of proteins and the immunomagnetic separation of Biomolecules, promoting innovation in downstream processing.
采用固定在亲和配体上的磁小体纳米颗粒(噬几丁质螺旋菌 MSR-1 细菌)作为免疫磁分离吸附剂,研究了具有高结合能力的重组乙型肝炎表面抗原(rHBsAg)的高效生物免疫磁分离(BIMS)。我们的结果表明,免疫磁吸附通过与固定化单克隆抗体的亲和相互作用,提供了比商业可得的免疫亲和吸附剂更高的抗原吸附和解吸容量。在通过吡啶二硫键功能化的磁小体纳米颗粒共价固定 Hep-1 单克隆抗体的过程中,考察了四种不同的配体密度对 HBsAg 免疫磁分离的影响。在优化的免疫磁分离吸附剂中,平均吸附容量为 3mg/ml(1.056mg rHBsAg/ml 免疫磁分离吸附剂/5.5mg 总纯化蛋白),在免疫亲和吸附剂中为 5mg/ml(0.876mg rHBsAg/ml 免疫吸附剂/5.5mg 总纯化蛋白),在 8 次运行中。免疫磁分离吸附剂在 12 个连续的免疫磁分离循环中表现出低于 3ng Mab/Ag rHBsAg 的配体泄漏水平。结果表明,与用于 r-HBsAg 亲和纯化的免疫吸附剂相比,具有较低配体密度(LD=3mg Mab/ml 基质)的免疫磁分离吸附剂可能是最佳替代品,在配体密度(98.59%(p 值=0.0182))、吸附容量(97.051%(p 值=0.01834))、解吸容量(96.06%(p 值=0.036))和回收率(98.97%(p 值=0.0231))方面均有显著差异。本研究表明,与目前用于大规模生产的 5mg Mab/ml 免疫亲和吸附剂相比,免疫吸附剂方法可将 Hep-1 蛋白的纯化成本降低 50%。此外,这些结果表明,细菌磁小体纳米颗粒(BMs)代表了一种有前途的替代产品,可用于经济高效地固定蛋白质和免疫分离生物分子,促进下游加工的创新。